Navigating Metastatic NSCLC Without Targetable Mutations: Frontline Strategies and Evolving Second-Line Options

Key Points

• The importance of next-generation sequencing (NGS) and PD-L1 levels in treatment decision-making.

• ⁠Current treatment options for patients with high PD-L1 scores, including single-agent immunotherapy.

• ⁠Strategies for patients with low or intermediate PD-L1 scores, including chemotherapy combined with immunotherapy.

• ⁠Discussion on KRAS G12C and HER2 positive disease in second-line settings, including the latest approved therapies.

• Insights into the potential side effects and considerations when transitioning from immunotherapy to targeted therapies.